Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Inborn Errors of Metabolism

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The fibrinogen αC region promotes arterial thrombosis in the context of hypofibrinogenemia.

Blood·2026

Same author

Genetic and clinical characteristics of congenital fibrinogen disorders in 10 Polish patients, with identification of 3 new variants: Fibrinogen Gdańsk II (FGB c.749A>G), Fibrinogen Gdańsk III (FGG c.246dupA), and Fibrinogen Toruń (FGB c.270delT).

Polish archives of internal medicine·2026

Same author

A Novel Heterozygous Mutation in FGB (c.1231_1232 del GA) Causing Hypofibrinogenemia With Mild Bleeding in a Large Swiss family.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Standardization of scanning electron microscopy analysis of fibrin fiber diameter measurement: communication from the ISTH SSC subcommittee on FXIII and fibrinogen.

Journal of thrombosis and haemostasis : JTH·2025

Same author

Gynecologic and obstetric complications in women with congenital fibrinogen disorders: insights from the Prospective Rare Bleeding Disorders Database.

Research and practice in thrombosis and haemostasis·2025

Same author

Management of Young and Ageing Women with Afibrinogenemia and Hypofibrinogenemia.

Hamostaseologie·2025

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Congenital fibrinogen disorders.

Philippe de Moerloose¹, Marguerite Neerman-Arbez

¹Division of Angiology and Haemostasis, University Hospital of Geneva, 1211 Geneva 14, Switzerland. Philippe.deMoerloose@hcuge.ch

Seminars in Thrombosis and Hemostasis

|July 15, 2009

Summary

Congenital fibrinogen disorders impact fibrinogen levels or function, causing bleeding or clotting. Molecular defect characterization is key for accurate diagnosis and personalized treatment strategies for these rare inherited conditions.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: Jun 21, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

Hematology
Molecular Biology
Genetics

Background:

Inherited fibrinogen disorders encompass quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia) defects, impacting fibrinogen levels or function.
These disorders can manifest as bleeding diathesis, paradoxical thrombotic episodes, or pregnancy loss, complicating clinical management.
Accurate diagnosis, even in specialized labs, can be challenging, necessitating advanced characterization methods.

Purpose of the Study:

To highlight the importance of molecular defect characterization in inherited fibrinogen disorders.
To discuss the diagnostic challenges and strategies, including the role of global hemostasis assays.
To emphasize the need for tailored replacement therapy and ongoing data collection for improved understanding and treatment.

Main Methods:

Review of existing literature on inherited fibrinogen disorders.
Discussion of diagnostic approaches, including molecular defect identification.
Analysis of clinical manifestations, genotype-phenotype correlations, and treatment strategies.

Main Results:

Molecular defect characterization aids in precise diagnosis, prenatal diagnosis, and risk stratification (bleeding vs. thrombosis).
Phenotype-genotype correlations are complex; global hemostasis assays offer better patient evaluation.
Replacement therapy is effective for bleeding but requires individualized treatment due to variable fibrinogen pharmacokinetics.

Conclusions:

Characterizing molecular defects is crucial for accurate diagnosis and management of inherited fibrinogen disorders.
Global hemostasis assays and tailored therapies improve patient outcomes.
Continued collection and comparison of molecular, biochemical, and clinical data are vital for advancing the understanding and treatment of these conditions.